554430-36-3

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 6496-89-5 2,4-dimethoxyphenylacetic acid 
• 554429-98-0 7-acetoxy-3-(2,4-dimethoxyphenyl)-4-methylcoumarin 
• 554430-37-4 3-[2,4-bis(2-trimethylsilylethoxymethoxy)phenyl]-4-bromomethyl-7-(2-trimethylsilylethoxymethoxy)coumarin 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 553681-50-8 4-methyl-3-(2,4-dihydroxyphenyl)-7-hydroxycoumarin 

Downstream Products

• 554430-46-5 3-[2,4-bis-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-4-(3-chloro-2-oxo-propyl)-7-(2-trimethylsilanyl-ethoxymethoxy)-chromen-2-one 
• 554430-37-4 3-[2,4-bis(2-trimethylsilylethoxymethoxy)phenyl]-4-bromomethyl-7-(2-trimethylsilylethoxymethoxy)coumarin 

Relevant academic research and scientific papers

Development of a scalable synthetic process for selective bromination of 4-methyl-3,7-substituted coumarins

The hydroxyl-protected coumarin derivatives 6a-e of 4-methyl-3-(2,4- dihydroxyphenyl)-7-hydroxycoumarin (4) are key intermediates in the synthesis of unsymmetrical benzopyranobenzopyran compounds, a novel series of selective estrogen receptor modulators (

Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators

The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators

The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.